A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Daiichi Sankyo Korea Co., Ltd..
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,204actual
Sites
33
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-16 | actual | When the study began enrolling |
| Primary completion | 2025-07-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-28 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation
Intervention
- Drug: Edoxaban
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Composite of Stroke, Systemic Embolic Events, Major Bleeding, or All-Cause Mortality
measured Baseline up to 12 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed